GILD · 8-K · 20260804PR000028

Acquisition / Partnership / Divestiture

GILEAD SCIENCES, INC. · 2026-08-04 · Importance 71 · Surprise 60 · In source text

Gilead completed the Tubulis acquisition for $3.15 billion of upfront consideration, adding the GS-8824 NaPi2b-directed topoisomerase-I inhibitor ADC and an ADC development platform. Gilead completed the Ouro Medicines acquisition for $1.675 billion upfront, adding gamgertamig, an investigational BCMAxCD3 T-cell engager for autoimmune diseases. Lakefront equally shared Ouro’s upfront payment and will equally share contingent milestone payments, subject to customary adjustments. Second-quarter acquired in-process research and development expense totaled $11.183 billion, including $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro, net of the Lakefront collaboration.

Key facts

• Acquired IPR&D expenses in Q2 2026: $11,183 million, primarily related to $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro Medicines, net of the impact of the Lakefront collaboration source
• Full year 2026 GAAP and non-GAAP diluted loss per share guidance includes approximately $9.08 per share due to acquired IPR&D charges of $11.1 billion related to Arcellx, Tubulis and Ouro Medicines transactions, net of Lakefront collaboration and related taxes source
• Gilead announced a renewed 5-year collaboration with the World Health Organization to commit funding, strategic support and AmBisome donations toward eliminating visceral leishmaniasis source
• The $(9.08) per share impact in Q2 2026 was due to acquired IPR&D and tax expenses associated with acquisitions of Arcellx, Tubulis and Ouro Medicines source

Impact estimates